Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 14/20 | 1.00 |
| ▸ | ITGAV | P06756 | 16/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lotrafiban SCHEMBL6673128 | 1.00 | ITGB3 (1.00) | ITGB3ITGA2BITGAV | |
| Lotrafiban SCHEMBL6673166 | 1.00 | ITGB3 (1.00) | ITGB3ITGA2BITGAV | |
| Lotrafiban SCHEMBL919968 | 0.99 | ITGB3 (0.98) | ITGB3ITGA2BITGAV | |
| Lotrafiban SCHEMBL4432242 | 0.98 | ITGB3 (0.96) | ITGB3ITGA2BITGAV | |
| SCHEMBL7499918 | 0.92 | ITGB3 (0.85) | ITGB3ITGA2BITGAV | |
| SCHEMBL8526301 | 0.90 | ITGB3 (0.82) | ITGB3ITGA2BITGAV | |
| SCHEMBL8194605 | 0.90 | ITGB3 (0.82) | ITGB3ITGA2BITGAV | |
| SCHEMBL6675548 | 0.88 | ITGB3 (0.79) | ITGB3ITGA2BITGAV | |
| SCHEMBL6958161 | 0.88 | ITGB3 (0.78) | ITGB3ITGA2BITGAV | |
| SCHEMBL6958164 | 0.88 | ITGB3 (0.78) | ITGB3ITGA2BITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1076 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| EP-4463485-A2 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2024-11-20 | — | — | EP | claimed |
| EP-4439040-A2 | HEPARIN-BASED BLOOD SAMPLER WITHOUT PLATELET ACTIVATION | Radiometer Medical ApS (DK) | 2024-10-02 | — | — | EP | claimed |
| CN-118384290-A | Hybrid immunoglobulins containing non-peptide linkages | 生物分子控股有限责任公司 | 2024-07-26 | — | — | CN | claimed |
| WO-2023137387-A2 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| WO-2023137373-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| US-20230220116-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-13 | — | — | US | claimed |
| US-20230220115-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-13 | — | — | US | claimed |
| EP-4178615-A1 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2023-05-17 | — | — | EP | claimed |
| US-11225490-B2 | Prodrugs of secondary amine compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-01-18 | — | — | US | claimed |
| EP-0964684-A4 | CRYSTALLINE PHARMACEUTICAL PRODUCT | SMITHKLINE BEECHAM CORP (US) | 2002-05-29 | — | — | EP | claimed |
| US-6335330-B1 | 7-((4,4*-BIPIPERIDIN-1-YL)CARBONYL)-2,3,4,5-TETRAHYDRO-4--METH YL-3-OXO-1H-1,4-BENZODIAZEPINE-2-ACETIC ACID HYDROCHLORIDE; FIBRINOGEN RECEPTOR ANTAGONITS, ANTICOAGULANTS; PREVENTION OF STROKES, RESTENOSIS | SMITHKLINE BEECHAM CORPORATION | 2002-01-01 | — | — | US | claimed |
| US-6117866-A | Bicyclic fibrinogen antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-09-12 | — | — | US | claimed |
| EP-0964928-A1 | ENZYMATIC RESOLUTION OF BENZODIAZEPINE-ACETIC ACID ESTERS WITH A LIPASE | SMITHKLINE BEECHAM PLC (GB) | 1999-12-22 | — | — | EP | claimed |
| EP-0964684-A1 | CRYSTALLINE PHARMACEUTICAL PRODUCT | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-22 | — | — | EP | claimed |
| WO-1998029561-A1 | ENZYMATIC RESOLUTION OF BENZODIAZEPINE-ACETIC ACID ESTERS WITH A LIPASE | SMITHKLINE BEECHAM PLC (GB) | 1998-07-09 | — | — | WO | claimed |
| WO-1998009629-A1 | CRYSTALLINE PHARMACEUTICAL PRODUCT | SMITHKLINE BEECHAM CORPORATION (US) | 1998-03-12 | — | — | WO | claimed |
| EP-0738150-A4 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1997-03-19 | — | — | EP | claimed |
| EP-0738150-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-10-23 | — | — | EP | claimed |
| WO-1995018619-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-07-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220115-A1 | TETRAHEDRAL ANTIBODIES | FCGR3B, FCGR2A, FCGR1A | ITGB3 672/4885ITGA2B 796/4885ITGAV 934/4885 |
| US-20230220116-A1 | TETRAHEDRAL ANTIBODIES | FCGR3B, FCGR2A, FCGR1A | ITGB3 672/4885ITGA2B 796/4885ITGAV 934/4885 |
| US-11225490-B2 | Prodrugs of secondary amine compounds | HNMT, MAOB, UGT1A1 | ITGB3 1314/4885ITGA2B 1164/4885ITGAV 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.